Identification of activating enzymes of a novel FBPase inhibitor prodrug, CS-917

CS-917 (MB06322) is a selective small compound inhibitor of fructose 1,6-bisphosphatase (FBPase), which is expected to be a novel drug for the treatment of type 2 diabetes by inhibiting gluconeogenesis. CS-917 is a bisamidate prodrug and activation of CS-917 requires a two-step enzyme catalyzed reac...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmacol Res Perspect
Main Authors: Kubota, Kazuishi, Inaba, Shin-ichi, Nakano, Rika, Watanabe, Mihoko, Sakurai, Hidetaka, Fukushima, Yumiko, Ichikawa, Kimihisa, Takahashi, Tohru, Izumi, Takashi, Shinagawa, Akira
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Ltd 2015
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4492754/
https://ncbi.nlm.nih.gov/pubmed/26171222
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.138
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados